The Clinical Effectiveness and Cost-Effectiveness of Rituximab Versus Natalizumab in Patients With Relapsing Remitting Multiple Sclerosis
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI